Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Tempus

Tempus
2015 FOUNDED
PRIVATE STATUS
601-700 EMPLOYEES
Series F LATEST DEAL TYPE
$200M LATEST DEAL AMOUNT
9 INVESTORS
Description

Developer of a health care data analytics platform designed to improve patient outcomes. The company's library of molecular and clinical data and an operating system provide genomic sequencing services as well as analyze molecular and therapeutic data to empower users to make real-time and data-driven decisions, enabling physicians to deliver personalized care for patients through an interactive analytical and machine learning platform.

Website
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Outcome Management (Healthcare)
Primary Office
  • 600 West Chicago Avenue
  • Suite 510
  • Chicago, IL 60654
  • United States

+1 (800) 000-0000
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Tempus’s full profile, request a free trial.

Tempus Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
6. Later Stage VC (Series F) 30-May-2019 $200M 00000 00.00 Completed Generating Revenue
5. Later Stage VC (Series E) 23-Aug-2018 00000 00000 00.000 Completed Generating Revenue
4. Later Stage VC (Series D) 23-Mar-2018 0000 00000 00.000 Completed Generating Revenue
3. Later Stage VC (Series C) 18-Sep-2017 0000 00000 00000 Completed Generating Revenue
2. Early Stage VC $50M $60M 00000 Completed Product Development
1. Early Stage VC 21-Sep-2015 $10M $10M 0000 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Tempus Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series F 0,000,000 00.000000 00 000.00 000.00 00 000.00 0.000
Series E 0,000,000 00.000000 00 000.00 000.00 00 000.00 0.00
Series D 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series C 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series B-2 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series B-1 0,000,000 00.000000 00 00 00 00 00 00
Series B 5,374,899 $0.000100 5% $1.86 $1.86 1x $1.86 4.29%
Series A 10,000,000 $0.000100 5% $1 $1 1x $1 7.99%
To view this company’s complete Cap Table, request access »

Tempus Competitors (46)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Oncology Analytics Venture Capital-Backed Atlanta, GA 00 000.00 00000000000 000.00
0000 Private Equity-Backed New York, NY 000 000.00 0000000 0000 000.00
000 0000000000 Venture Capital-Backed Cambridge, MA 00 000.00 00000000000 000.00
0000000000 Venture Capital-Backed La Jolla, CA 00 0000000000
0000000000000 Venture Capital-Backed Cleveland, OH 00.000 0000000000 0 00.000
To view this company’s complete list of competitors, request access »

Tempus Investors (9)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Franklin Templeton Investments Asset Manager Minority 000 0000 000000 0
Novo Holdings Corporate Venture Capital Minority 000 0000 000000 0
Revolution Group Venture Capital Minority 000 0000 000000 0
Baillie Gifford Asset Manager Minority 000 0000 000000 0
Kinship Trust Company Family Office Minority 000 0000 000000 0
You’re viewing 5 of 9 investors. Get the full list »

Tempus Executive Team (12)

Name Title Board
Seat
Contact
Info
Vanessa Rollings Chief Financial Officer
Ryan Fukushima Chief Operating Officer
Marc Yoskowitz JD Chief Strategy Officer
Shane Colley Chief Technology Officer
Kevin White Ph.D Chief Science Officer

1 Former Executive

You’re viewing 5 of 12 executives. Get the full list »

Tempus Board Members (6)

Name Representing Role Since Contact
Info
Bradley Keywell JD Self Founding Investor & Board Member 000 0000
Eric Lefkofsky JD Self Founder, Board Member & Chief Executive Officer 000 0000
Peter Barris New Enterprise Associates Advisor & Board Member 000 0000
Robert Ghenchev Novo Holdings Board Member 000 0000
Steven Murray Self Board Observer 000 0000
You’re viewing 5 of 6 board members. Get the full list »